Intellia Therapeutics NTLA
NASDAQ NTLA
$11.96 -0.07 (-0.58%)
As of: Sep 30, 2026 · 10:25 AM EDT

Intellia Therapeutics (NTLA) EBITDA Margin (2015 - 2026)

Updated

Intellia Therapeutics' EBITDA Margin was -1444.84% in Q2 2026, down 690.21 percentage points from -754.62% a year earlier and down 791.39 percentage points from the prior quarter.

Analysis

Intellia Therapeutics (NTLA) EBITDA Margin (2015 - 2026) Analysis & Trends

On a trailing twelve-month basis, Intellia Therapeutics' EBITDA Margin was -696.36% through Jun 30, 2026, up 253.07 percentage points year-over-year; for FY2025, it came in at -637.19%, up 268.12 percentage points from FY2024.

  • EBITDA Margin shows a five-year change of -412.56 percentage points (FY2020 to FY2025).
  • In earlier years, EBITDA Margin was -905.30% in FY2024 (+490.40 pp), -1395.70% in FY2023 (-531.24 pp), -864.46% in FY2022 (-74.97 pp) and -789.49% in FY2021 (-564.86 pp).
  • The Q2 2026 figure marks the lowest quarterly EBITDA Margin since Q3 2024.
  • Compared with a year earlier, EBITDA Margin was higher in four of the last seven quarters, with an average year-over-year change of +164.63 percentage points.
  • The best year-over-year quarter for EBITDA Margin over five years was Q2 2025 (a gain of 1206.61 percentage points); the worst was Q2 2024 (a drop of 1003.72 percentage points).
  • Per Business Quant data, NTLA's EBITDA Margin in the three quarters before Q2 2026 was -653.44% (Q1 2026), -418.43% (Q4 2025) and -791.45% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 35.95%
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 49.01%
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 6.02%
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 33.11%
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 46.01%
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -124.26%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 39.10%
10 Intellia Therapeutics 1.60 Bn 1.60 Bn - -1,444.84%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -1,444.84%
Mar 31, 2026 -653.44%
Dec 31, 2025 -418.43%
Sep 30, 2025 -791.45%
Jun 30, 2025 -754.62%
Mar 31, 2025 -711.54%
Dec 31, 2024 -1,039.82%
Sep 30, 2024 -1,560.42%
Jun 30, 2024 -1,961.23%
Mar 31, 2024 -385.32%
Sep 30, 2023 -1,074.19%
Jun 30, 2023 -957.51%
Mar 31, 2023 -871.87%
Dec 31, 2022 -795.90%
Sep 30, 2022 -780.79%
Jun 30, 2022 -687.56%
Mar 31, 2022 -1,266.37%
Dec 31, 2021 -610.91%
Sep 30, 2021 -974.56%
Jun 30, 2021 -1,028.75%
API Access

Intellia Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=NTLA&period=max&api_key=YOUR_API_KEY